Clerkenwell Health

What Clerkenwell Health does

Clerkenwell Health (legal entity: Clerkenwell Clinics Limited) is a London-based, privately held clinical research organisation (CRO) founded in 2021 that specialises in central nervous system (CNS) clinical trials, with lead capability in psychedelic-assisted therapy. The company operates a purpose-built UK site network currently comprising three facilities: Welbeck Street in central London (3 dosing rooms), Baker Street in central London (6 dosing rooms plus a Home Office Schedule 1-4 licensed pharmacy), and the UK's first NHS-embedded CNS research site at Doncaster (8 treatment rooms, in partnership with Rotherham Doncaster and South Humber NHS Foundation Trust). Two additional sites are planned by the end of 2026.

The service portfolio is organised into four integrated modules — Trial Design, Submission & Approvals; Trial Management; Trial Delivery; and Clinical Talent & Training — delivered through a centralised recruitment engine drawing on a 50,000+ participant registry, more than 40,000 active vetted patients, and a network of over 500 trained practitioners. Underlying operational technology includes an iPassport QMS for SOP, training and compliance management and a CRIO platform for scheduling, screening and recruitment tracking; a patient-facing e-health app is described as under development. Regulatory capability is evidenced by Home Office Schedule 1-4 licences, ICH-GCP compliance, and a 100% Clinical Trial Application approval rate.

The company operates a B2B, fee-for-service enterprise model selling directly to pharmaceutical sponsors, biotech firms, and CROs via a dedicated field sales motion ([email protected]). Pricing is not publicly disclosed and engagements are bespoke multi-year contracts tied to study complexity. Disclosed customers include Octarine Bio and two undisclosed clients; the principal investigator bench carries active study experience with AbbVie, AstraZeneca, Lilly, Lundbeck, GSK, Novo Nordisk, Compass, Cybin, MindMed, and Transcend. The company is venture-backed, having closed a £2.1 million seed round in October 2022 led by Convergence Partners, Exceptional Ventures, and Lionheart Ventures.

Name

Clerkenwell Health

Legal name

Clerkenwell Clinics Limited

Website

https://clerkenwellhealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Clerkenwell Health is a London-based, privately held CRO founded in 2021 that runs CNS and psychedelic-assisted therapy clinical trials for pharmaceutical sponsors, biotech firms, and other CROs through a purpose-built, three-site UK network including an NHS-embedded facility.

Ownership category

akta.pro rank

Product category

Clinical Research Organization Services

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• CNS clinical trials
• Psychedelic therapy research
• Contract research services
• Mental health trials
• Specialist site network

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Trial Services for Sponsors & CROs: End-to-end CNS trial services including trial design, regulatory submissions, trial management, and delivery through purpose-built site network. Revenue generated from fees for service across project management, site operations, patient recruitment, and regulatory support.
2. Site Network Access Fees: Single-contract access to scalable, harmonised site network across multiple UK locations for sponsors running CNS clinical trials.
3. Clinical Talent & Training Services: Access to CNS-experienced Principal Investigators, trained therapists, and certified raters for clinical trials. Also includes practitioner recruitment, training and ongoing competency monitoring.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Clerkenwell Health is a UK-based clinical research organisation (CRO) specialising in central nervous system (CNS) and psychedelic-assisted therapy clinical trials. It designs, manages and delivers end-to-end trials through a purpose-built site network in London and Doncaster, including NHS-embedded facilities holding Home Office Schedule 1-4 licences, and supplies CNS-experienced principal investigators, trained therapists and certified raters.

Product overview

Clerkenwell Health operates as a clinical research organization (CRO) specializing in CNS and psychedelic-assisted therapy trials. The company offers an integrated service portfolio comprising four core modules: Trial Design, Submission & Approvals; Trial Management; Trial Delivery; and Clinical Talent & Training. These services are delivered through a purpose-built UK site network spanning three locations (London Welbeck Street, London Baker Street, and Doncaster NHS partnership) with two additional sites planned by end of 2026. The company is also developing a patient-facing ehealth app to support treatment delivery at scale. Services focus on psychedelic compounds (psilocybin, DMT, 5-MeO-DMT, MDMA, MM120) and broader CNS indications across psychiatry and neurology.

Differentiator

Problem solved

Functional benefit

Products and services

• Trial Design, Submission & Approvals Expert protocol design, regulatory strategy and translational support from concept through approval for CNS clinical trials, including early-stage and translational support, regulatory affairs and submissions, feasibility and site selection, and medical writing for pharmaceutical sponsors and biotech companies.
• Trial Management Full end-to-end project oversight ensuring CNS trials stay on track, on budget, and deliver quality data, covering project and risk management, regulatory and quality oversight, vendor/budget/operational management, clinical monitoring and site oversight, data management and biostatistics, and safety and medical monitoring for pharmaceutical sponsors.
• Trial Delivery Execution of CNS trials through Clerkenwell Health's purpose-built UK site network with centralised coordination and a patient-centric approach, including site network delivery and operations, patient recruitment and retention, and specialist CNS and psychedelic procedures for pharmaceutical sponsors and CROs.
• Clinical Talent & Training Access to CNS specialist Principal Investigators, trained therapists and certified raters for psychedelic and CNS research, including central raters, therapist and practitioner network, and practitioner recruitment, training and ongoing competency monitoring for clinical trial sponsors.
• London Welbeck Street Site Purpose-built CNS research facility in central London (Welbeck Street, W1G 8DR) with 3 dedicated treatment and dosing rooms designed for CNS protocols, located near Bond Street and Oxford Circus underground stations, serving Greater London and South East England.
• London Baker Street Site Purpose-built CNS research facility in central London (Baker Street, W1U 6RP) with 6 dedicated treatment and dosing rooms, a Home Office licensed pharmacy (Schedules 1-4), an on-site laboratory, serving Greater London and South East England with a >40,000 active vetted patient database.
• Doncaster Site (NHS Partnership) UK's first NHS-embedded CNS research site at Tickhill Road Hospital, Balby, Doncaster DN4 8QN, operated in partnership with Rotherham Doncaster and South Humber NHS Foundation Trust (RDaSH), with 8 dedicated treatment and dosing rooms, serving South Yorkshire and the North of England with access to 32k+ patient records through the NHS partnership.

Quantifiable outcome

• 50% higher retention rate throughout study duration compared to industry benchmarks
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• Psyence (Toronto)coreStrategic or Co-development Partner · 10 October 2022Collaboration with Toronto-based Psyence for psilocybin-assisted therapy clinical trials. Clerkenwell Health's first clinical trial in London for terminally ill patients involves partnerships with Psyence and North American biotechnology companies.
• North American Biotechnology CompaniescoreStrategic or Co-development Partner · 10 October 2022Collaboration with North American biotech companies for psychedelic-assisted therapy trials. Multiple partnerships supporting the start of psilocybin-assisted therapy trials for terminally ill patients.
• Rotherham Doncaster and South Humber NHS Foundation Trust (RDaSH)coreStrategic or Co-development PartnerUK's first NHS-embedded CNS research site created in partnership with RDaSH. Enables faster start-up through commercial processes, smoother recruitment via NHS pathways, and greater patient trust. Clerkenwell Health's research team works alongside NHS physicians, nurses and therapists.
• Octarine BiocoreStrategic or Co-development PartnerWorking with drug development company Octarine Bio to design and deliver clinical trials for psilocybin and its analogues. One of three clients the company was working with early in operations.
• UK NHS Trusts & GP NetworksmajorChannel Partner/ Reseller/ DistributorStrategic partnerships providing access to NHS and GP referral pathways for patient recruitment. Access to 32k+ patient records through NHS partnership at Doncaster site. Enables connection of underserved populations to trials.
• Charitable OrganizationsminorChannel Partner/ Reseller/ DistributorCharity partnerships contributing to centralised recruitment engine alongside NHS trusts and GP networks.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• COMPASS Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Comparable because it runs large psilocybin trials and is a likely sponsor customer of Clerkenwell's psychedelic site network, while also representing an internal in-sourced alternative for sponsors.
• Parexel: Top-five global CRO with extensive CNS, neurology and psychiatry clinical operations. Comparable because it serves the same pharmaceutical sponsor base for CNS trials and could in-source or compete with specialist psychedelic site networks as psychedelic pipelines mature.
• IQVIA: Largest global CRO with broad CNS, neuroscience and real-world evidence capabilities. Comparable because it is the CEO's former employer, already serves the same large-pharma CNS sponsor base, and represents the scale incumbent that Clerkenwell must differentiate against.
• Worldwide Clinical Trials: Mid-sized global CRO with a leading CNS and neuroscience franchise across Phase I–IV trials. Comparable because it competes for the same pharma/biotech CNS trial budgets that Clerkenwell targets, but at much larger global scale.
• MindMed: Clinical-stage psychedelic medicine company developing LSD and MDMA-based therapies for CNS indications. Comparable because it sponsors psychedelic trials (referenced as a Clerkenwell past engagement) and competes for sponsor mindshare in psychedelic CNS trial design and execution.

Direct peers

• Cybin: Clinical-stage psychedelic therapeutics company with deuterated psilocybin and other CNS programmes. Comparable because it is named among Clerkenwell's prior study sponsors and operates in the same psychedelic-assisted therapy trial category.
• Panthera Biopartners: UK-focused CRO running commercial clinical trials across multiple therapy areas including CNS. Comparable because it directly competes for sponsor CNS trial placements in the UK and is a previous employer of Clerkenwell's Senior Clinical Research Physician.
• Beckley Psytech: UK-based clinical-stage psychedelic medicine company developing psilocybin and DMT-based therapies. Comparable because it shares Clerkenwell's UK base and CNS/psychedelic therapy focus and represents an adjacent competitor-sponsor in the same regional market.
• MAC Clinical Research: UK-based early- and late-phase clinical research organisation with a strong CNS franchise across multiple therapy areas. Comparable because it competes for CNS trial work in the UK and is a previous employer of Clerkenwell's Senior Clinical Research Physician.

Emerging players

• Sana Biotechnology (CNS/psychiatry units) / Pharm-Olam: Mid-sized CRO with growing CNS and rare-disease capabilities including psychedelic-adjacent programmes. Comparable because it competes for specialist CNS/psychiatry trial work where Clerkenwell differentiates on psychedelic expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/clerkenwell-health
• Xx.com/clerkenwell_uk

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clerkenwell Health